Selective Cytopheresis Therapy in Systemic Inflammatory Response Syndrome

全身炎症反应综合征的选择性细胞分离疗法

• 批准号: 7940401
• 负责人: DEBORAH Ann BUFFINGTON
• 金额: $ 7.58万
• 依托单位: INNOVATIVE BIOTHERAPIES, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-03-01 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7940401
• 关键词: Adult Respiratory Distress Syndrome; Animals; Antibiotics; Area; Bacteria; Blood Pressure; Bronchoalveolar Lavage; Cardiovascular system; Cessation of life; Clinical; Data; Devices; Disease; Disease Progression; Drug Formulations; Family suidae; Functional disorder; Hour; Inflammation; Inflammatory; Inflammatory Response; Innovative Therapy; Intensive Care Units; Investigation; Lead; Leukocytes; Marketing; Membrane; Modeling; Names; Pathogenesis; Patients; Phase; Placebos; Pneumonia; Pre-Clinical Model; Process; Proteins; Pump; Renal tubule structure; Reperfusion Injury; Research Proposals; Sepsis; Sepsis Syndrome; Septic Shock; Site; Small Business Innovation Research Grant; Surface; System; Testing; Therapeutic; Time; Tissues; cytokine; improved; mortality; neutrophil; novel therapeutic intervention; research study

DESCRIPTION (provided by applicant): An extracorporeal device, named selective cytopheretic device (SCD), has been fabricated that sequesters activated leukocytes and inhibits their release of inflammatory proteins and cytokines. Leukocytes are major contributors to the pathogenesis and progression of many clinical inflammatory disorders, including the systemic inflammatory response syndrome (SIRS), sepsis and acute respiratory distress syndrome (ARDS). A large number of therapeutic approaches are under investigation to limit the activation and tissue accumulation of leukocytes at sites of inflammation in order to minimize tissue destruction and disease progression. This research proposal will evaluate this SCD on a well-developed porcine model of septic shock, SIRS and early ARDS. Various cardiovascular parameters, systemic cytokine levels, and pulmonary inflammation with bronchoalveolar lavage (BAL) parameters and time to death will be compared between treatment and sham treatment groups. The effects of membrane surface area and efficacy of a simplified circuit system on the ongoing multiorgan dysfunction and inflammatory processes will also be assessed. This proposal may suggest a manner of altering the systemic inflammatory response and may lead to a new therapeutic approach to sepsis, SIRS and ARDS.

描述（由申请人提供）：已制造出一种称为选择性细胞生物装置（SCD）的体外装置，已制造出隔离器激活白细胞并抑制其释放炎症蛋白和细胞因子的释放。白细胞是许多临床炎性疾病的发病机理和进展的主要因素，包括全身性炎症反应综合征（SIRS），败血症和急性呼吸遇险综合征（ARDS）。正在研究大量的治疗方法，以限制白细胞在炎症部位的激活和组织积累，以最大程度地减少组织破坏和疾病进展。该研究建议将根据发达的脓毒症，SIRS和早期ARDS的猪猪模型评估该SCD。在治疗组和假治疗组之间，将比较各种心血管参数，全身细胞因子水平和肺部炎症（BAL）参数（BAL）参数（BAL）参数和死亡时间。还将评估膜表面积和简化电路系统对正在进行的多器官功能障碍和炎症过程的影响。该提案可能提出一种改变系统性炎症反应的方式，并可能导致对败血症，先生和ARDS的新治疗方法。